<DOC>
	<DOCNO>NCT01619644</DOCNO>
	<brief_summary>An exploratory phase 2 therapeutic trial child 6 21 , RTS carrier , randomize treat either sodium valproate usual pediatric dosage ( 30 mg/kg/j ) , placebo one year . The investigator would like include child could best profit due neuronal plasticity CBP EP300 take effect neuronal synaptic plasticity . The therapeutic effect sodium valproate RTS patient assess thanks clinical approach ( learn memory neuropsychological evaluation , fine motor skill assessment point ) , biological approach ( histone acetylation functional test ) , image ( morphological functional MRI ) .</brief_summary>
	<brief_title>Rubinstein-Taybi Syndrome : Functional Imaging Therapeutic Trial</brief_title>
	<detailed_description>Such multidisciplinary approach never present syndrome ; enable u identify specific cognitive motor deficit association thanks image marker . Assessing various aspect motor skill , i.e . primary ( movement , stand ease position , immobility ) complex motor skill ( action behaviour , motor aspect feeling language expression ) integral part clinical examination psychiatrics . The main interest functional capacity analysis use index allow assessment nervous system 's global capacity study connection cognitive function motor skill Main objective : Evaluate long term memory subtest `` point location '' - CMS `` image recognition '' RBMT A patient say responder one year test result increase one point least one two test : increase one point `` point location '' `` image recognition '' . Double-blind phase 2 clinical trial , design one-step Fleming design control group . Rubival two-parallel group randomize trial : - placebo group 20 patient - group 40 patient take sodium valproate ( HDAC inhibitor ) oral dosage 30 mg/kg/jour</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Rubinstein-Taybi Syndrome</mesh_term>
	<mesh_term>Hand Deformities , Congenital</mesh_term>
	<mesh_term>Osteochondrodysplasias</mesh_term>
	<mesh_term>Craniofacial Abnormalities</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>Children 6 21 RTS confirm genetic study CBP gene EP300 gene mutation Sufficient cognitive capacity neuropsychological evaluation Free inform consent parent guardians Children affiliate benefit French social welfare system Contraindication sodium valproate Women reproductive age without effective contraception mean Case history sodium valproate treatment Monotherapy treatment epilepsy Lamictal dosage superior 5 mg/kg/j Family history severe hepatitis include drug Acute chronic hepatitis Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>RTS</keyword>
	<keyword>Rubinstein Taybi</keyword>
	<keyword>explorative phase 2</keyword>
	<keyword>clinical approach</keyword>
	<keyword>biological approach</keyword>
	<keyword>motor skill</keyword>
</DOC>